One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Capricor Therapeutics just hit that mark, with a jump from 69 to 86 Thursday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they begin their biggest price moves.
Capricor Therapeutics is now considered extended and out of buy range after clearing a 5.48 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported 0% earnings growth in its most recent report. Sales rose -100%. Look for the next report on or around Aug. 7.
Capricor Therapeutics holds the No. 286 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
